Arca
Skip to content

Hidradenitis suppurativa

Drug research and approvals for hidradenitis suppurativa: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 57 studies of hidradenitis suppurativa are recruiting on ClinicalTrials.gov, Health Canada has authorized 57 drug trials for it since 2013, FDA has 2 approved and 0 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 57
  • Trials authorized in Canada: 57
  • FDA orphan approvals: 2
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 57 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 57; search them all in Canada trials
Nov 12, 2026Hidradenitis suppurativa: a phase 2 multicenter platform study of targeted therapies for the treatment of adult subjectsABBV-295 / LUTIKIZUMAB (ABT-981)AbbViePending
Sep 17, 2026“a phase 2b, randomized, double-blind, placebo-controlled, parallel group, doseranging study to evaluate the efficacy and safety of duvakitug in adult…DUVAKITUG (SAR447189)SANOFI-AVENTIS CANADA INCOngoing
Aug 25, 2026A phase 2, randomized, double-blind, placebo-controlled, parallel-group 52 week trial to investigate the efficacy and safety of olatorepatide, a glp-1/gip…OLATOREPATIDE (HS-20094)RegeneronPending
Aug 7, 2026A multicenter, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of orka-002 in adult…ORKA-002ORUKA THERAPEUTICS, INC.Ongoing
Aug 7, 2026A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-ofconcept trial to assess the efficacy and safety of spy072 in adults with moderate…SPY002-072SPYRE THERAPEUTICS, INC.Ongoing
Jun 10, 2026A double-blind, double-dummy, parallel group, multicenter phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in…REMIBRUTINIB (LOU064)Novartis Pharmaceuticals CorporationOngoing
Dec 19, 2025A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of nav-240 in adult participants with moderate-to-severe hidradenitis suppurativaNAV-240NAVIGATOR MEDICINES, INC.Ongoing
Dec 15, 2025A phase 2, multicenter, randomized, double-blind, placebo- controlled trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis…ZASOCITINIB (TAK-279)Takeda Pharmaceuticals USAOngoing
Dec 11, 2025A randomized, double-blind, placebo-controlled, phase 2, dose-finding study to investigate the efficacy and safety of sar445399 in participants with moderate…KEVZARASANOFI-AVENTIS CANADA INCOngoing
Nov 19, 2025A randomized, double-blind, placebo-controlled, phase 2, dose-finding study to investigate the efficacy and safety of sar445399 in participants with moderate…SAR445399SANOFI-AVENTIS CANADA INCOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 16, 2018HUMIRATreatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.AbbVie, Inc.Approved
Sep 9, 2015HUMIRATreatment of moderate to severe hidradenitis suppurativaAbbVie, Inc.Approved

Medicines Authorised in the EU

Newest first
Sep 17, 2018Hulioadalimumab · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Jan 14, 2015CosentyxsecukinumabNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.